

09/980 266

Sheet

3 of 1001

Form 100 (Rev. 10-1997)

U.S. Dept. of Commerce  
Patent and Trademark Office

ATTY. DOCKET NO.

SERIAL NO.

HUBR 1198 (1011154)

Please assign

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT

Kratz

FILING DATE

herewith

GROUP

To Be Assigned

**U.S. PATENT DOCUMENTS**

*Examiner Initial	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (if appropriate)

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
RT	196 36 889	3 12 98	DE				
I	00 76550	12 21 00	WO				

**OTHER DOCUMENTS**

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

RT	1	Kratz, et al "Preparation, Characterization and In Vitro.....Doxorubicin", Biological & Pharm. Bulletin, Pharm. Soc. of Japan, Vol. 21, No. 1, 1998, pages 56-61
	2	A. Trouet, et al, "A covalent linkage between daunorubicin and proteins that is ....in vivo studies", Proceedings of the National Academy of Sciences of USA, Vol. 79, 1:82 (pages 626-629).
	3	S. Netzel-Arnett, "Comparative Sequence..... (Matrilysin)", Biochemistry, Vol. 32, No. 25, 1993, pages 6427-6432.
	4	M. Nichifor et al: "Macromolecular prodrugs of 5-fluorouracil ...degradation", Journal of Controlled release, Vol. 39, 1996, pages 79-92.
	5	G. M. Dubowchik et al: "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study.....doxorubicin", Biorg. Med. Chem. Lett. Vol. 8, No. 23, pages 3341-3346.
	6	M. Kruger, et al: "synthesis and stability of four maleimide.....chemoimmunoanjugates", Biological & Pharm. Bull. of Japan, Vol. 45, No. 2, 1997, pages 399-401.

EXAMINER

R. Teller

DATE CONSIDERED

12/22/03

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.